Advertisement

Nimodipin

  • H. Herrschaft

Zusammenfassung

Wie andere Stoffe dieser Substanzklasse verhindert Nimodipin den Einstrom von Calciumionen durch die spannungs- und rezeptoraktivierten Kanäle der Zellmembranen über eine Interaktion mit spezifischen, hochaffinen Bindungsstellen und bewirkt eine Tonusminderung der glatten Muskelzellen der Blutgefäße (Cauvin et al. 1983, Fleckenstein-Grün et al. 1985, Glossmann et al. 1985, van Zwieten 1986).

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Allen GS, Ahn HS, Preziosi TJ, Battye R, Boone SC et al. (1983) Cerebral arterial spasm: a controlled trial of nimodipine in patients with subarachnoid hemorrhage. N Engl J Med 308: 619–624PubMedGoogle Scholar
  2. Auer LM (1982) Pial arterial and venous reaction to intravenous infusion of nimodipine in cats. J Neurosurg Sci 26: 213–218PubMedGoogle Scholar
  3. Auer LM, Mokiry M (1985) Effect of topical nimodipine versus its ethanol-containing vehicle on cat pial arteries. Stroke 17: 225–228Google Scholar
  4. Auer LM, Oberhauser RW, Schalk HV (1983) Human pial vascular reactions to intravenous nimodipine infusion during EC-IC bypass surgery. Stroke 14: 210–213PubMedGoogle Scholar
  5. Auer LM, Suzuki A, Yasui N, Ito Z (1984) Intraoperative topical nimodipine after aneurysm clipping. Neurochirurgia 27: 36–38PubMedGoogle Scholar
  6. Auer LM, Brandt L, Ebeling U, Gilsbach J, Groeger U et al. (1986) Nimodipine and early aneurysm operation in good condition SAH patients. Acta Neurochir 82: 7–13PubMedGoogle Scholar
  7. Barnett GH, Bose B, Little JR, Jones SC, Friel HT (1986) Effects of nimodipine on acute focal cerebral ischaemia. Stroke 17: 886–890Google Scholar
  8. Ban TA, Morey L, Aguglia E, Azzarelli O, Balsano F, Marigliano V, Caglieris N, Sterlicchio M, Capurso A, Tomasi NA, Crepaldi G, Volpe D, Palmieri G, AMBROSI G, Pow E, Cortellaro M, Zanussi C, Froldi M (1990) Nimodipine in the treatment of old age dementias. Prog Neuro-Psychopharmacol Biol Psychiatry 14: 525–551Google Scholar
  9. Baumel B, Eisner LS, Karukin M, Macnamara R, Raphan H (1989) Nimodipine in the treatment of Alzheimer’s disease. In: Bergener M, Reisberg B (eds) Diagnosis and treatment of senile dementia. Springer, Berlin Heidelberg New York Tokyo, pp 336–373Google Scholar
  10. Bianchi AP, Viglianesi MS (1985) Hemorrheological effects of dihydropyridine calcium entry blockers. Naunyn Schmiedebergs Arch Pharmacol (abstract no. 154) 330: 87Google Scholar
  11. Bielenberg GW, Beck T, Saver D, Burniol M, Krieglstein J (1987) Effects of cerebroprotective agents on cerebral blood flow and on postischämic energy metaboolism in the rat brain. J Cereb Blood Flow Metab 7: 480–488PubMedGoogle Scholar
  12. Bomhard E, Luckhaus G (1975) Bay e 9736. Subchronic toxicity study in rats (trial with administration over 3 months). PB 5360, Toxizitätsstudien. Archiv-Daten. Bayer AG, LeverkusenGoogle Scholar
  13. Bomhard E, Nash G, Vogel O (1982) Bay e 9736 — Chronic toxicological observations on rats (two-year feed test). PB 10756, — Toxizitätsstudien. Archiv-Daten. Bayer AG, LeverkusenGoogle Scholar
  14. Brandt L, Ljunggren B, Saveland H, Andersson K-A, Vinge E (1986) Cerebral vasospasm and calcium channel blockade. Acta Pharmacol 58 [Suppl 2]: 151–155Google Scholar
  15. Bruckner GW, Jansen W (1979) Über den Einfluß einer 10-wöchigen Therapie mit Nimodipin auf Symptomatik und cerebrale Leistungsfähigkeit von Alterspatienten mit cerebrovaskulärer Insuffizienz. Bayer AG, leverkusen (unveröffentlicht)Google Scholar
  16. Cauvin C, Loutzenhiser R, Van Breemen C (1983) Mechanisms of calcium antagonist-induced vasodilation. Ann Rev Pharmacol Toxicol 23: 373–396Google Scholar
  17. Detzer K, Luckhaus G, Nash G (1981) Bay e 9736 — Test of the systemic and local tolerance on beagles after intravenous drip infusion for 4 weeks. PB 10323, Toxizitätsstudien. ArchivDaten. Bayer AG, LeverkusenGoogle Scholar
  18. Deyo R, Straube K, Disterhoft J (1989) Nimodipine facilitates associative learning in aging rabbits. Science 243: 809–811PubMedGoogle Scholar
  19. Disterhoft J, Black J, Deyo R, Straube K, Thompson L (1989) Associative learning in aging rabbits is facilitated by nimodipine. In: Traber J, Gispen WH (eds) Nimodipine and central nervous system function: new vistas. Schattauer, Stuttgart New York, pp 209–225Google Scholar
  20. Dorn M (1985) Effect of nimodipine on the wellbeing, symptoms and efficacy of ambulatory patients with cerebrovascular disorders. In: Betz E, Deck K, Hoffmeister F (eds) Nimodipine. Pharmacological and clinical properties. Proceedings of the 1st International Symposium, München, Feb. 1984. Schattauer, Stuttgart New York, pp 295–304Google Scholar
  21. Finger S, Dunnett SB (1989) Nimodipine and neural grafts. In: Traber J, Gipsen WH (eds) Nimodipine and central nervous system functions: new vistas. Schattauer, Stuttgart New York, pp 87–98Google Scholar
  22. Finger S, Green L, Tarnoff ME, Mortman KD, Andersen A (1990) Nimodipine enhances new learning after hippocampal damage. Exp Neurol 109: 279–285PubMedGoogle Scholar
  23. Fischhof PK, Rüther E, Wagner G, Litschauer G (1990) Therapieergebnisse mit Nimodipin bei primär degenerativer Demenz und Multiinfarktdemenz. Z Geriatrie 3: 320–327Google Scholar
  24. Fleckenstein-Grün G, Frey M, Makita Y, Byon YK (1985) New pharmacological aspects of various dihydropyridine calcium antagonists with regard to smooth muscle relaxation. In: Lichtlen PR (ed) Recent aspects in calcium antagonism. Schattauer, Stuttgart New York, pp 29–46Google Scholar
  25. Gaab MR, Haubitz I, Brawanski A, Korn A, Czech TH (1985) Acute effects of nimodipine on the cerebral blood flow and intracranial pressure. Neurochirurgia 28: 93–99PubMedGoogle Scholar
  26. Gelmers HJ (1982) Effect of nimodipine (Bay e 9736) on postischaemic cerebrovascular reactivity, as revealed by measuring regional cerebral blood flow (rCBF). Acta Neurochir 63: 283–290PubMedGoogle Scholar
  27. Gelmers HJ (1984) The effects of nimodipine on the clinical course of patients with acute ischaemic stroke. Acta Neurol Scand 69: 232–239PubMedGoogle Scholar
  28. Gelmers HJ, Gorter K, De Weerdt CJ, Weizer HAJ (1988) A controlled trial of nimodipine in acute ischaemic stroke. N Engl J Med 318: 203–207PubMedGoogle Scholar
  29. Gengo FM, Fagan SC, Krol G, Bernhard H (1987) Nimodipine disposition and haemodynamic effects in patients with cirrhosis and age-matched controls. Br J Clin Pharmacol 23: 47–53PubMedGoogle Scholar
  30. Gerritsen Van Der Hoop R, Van Der Zee Ceem, Gispen WH (1989) Nimodipine and neural plasticity. In: Bergener M, Reisberg B (eds) Diagnosis and treatment of senile dementia. Springer, Berlin Heidelberg New York, pp 288–294Google Scholar
  31. Gioia AE, White RP, Bakhtian B, Robertson JT (1985) Evaluation of the efficacy of intrathecal nimodipine in canine models of chronic cerebral vasospasm. J Neurosurg 62: 721–728PubMedGoogle Scholar
  32. Glossmann H, Go UA, Rombusch M, Ferry DR (1985) Molecular pharmacology of Ca2+ channels: receptor binding studies. In: Betz E et al. (eds) Nimodipine: pharmacological and clinical properties. Schattauer, Stuttgart New York, pp 147–161Google Scholar
  33. Hakim AM, Evans AC, Berger L, Kuwabara H, Worsley K, Marchal G, Biel C, Pokrupa P, Diksic M, Meyer E, Gjedde A, Pokrupa R (1989) The effect of nimodipine on the evolution of human cerebral infarction studied by Pet. J Cereb Blood Flow Metab 9: 523–534PubMedGoogle Scholar
  34. Harper AM, Craigen L, Kazda S (1981) Effect of the calcium antagonist, nimodipine, on cerebral blood flow and metabolism in the primate. J Cereb Blood Flow Metab 1: 349–356PubMedGoogle Scholar
  35. Hadley MN, Zabramski JM, Spetzler RF, Rigamonti D, Fifield MS (1989) The efficacy of intravenous nimodipine in the treatment of focal cerebral ischemia in a primate model. Neurosurgery 25: 63–70PubMedGoogle Scholar
  36. Harwart H, Biastock E (1982) Kontrollierte Doppelblindstudie bei Patienten mit Hirnleistungsstörungen im Alter. Bayer AG, Leverkusen (unveröffentlicht)Google Scholar
  37. Haws CW, Heistad DD (1984) Effects of nimodipine on cerebral vasoconstrictor responses. Am J Physiol 247: H170–H176Google Scholar
  38. Haws CW, Gourley JK, Heistad DD (1983) Effects of nimodipine on cerebral blood flow. J Pharmacol Exp Ther 225: 24–48PubMedGoogle Scholar
  39. Held K, Boehme K, Rode PC (1985) Efficacy and tolerability of nimodipine in patients with oldage cerebrovascular dysfunction. In: Betz E, Deck K, Hoffmeister F (eds) Nimodipine: pharmacological and clinical properties. Proceedings of the 1st International Symposium, München, Feb. 1984. Schattauer, Stuttgart New York, pp 289–292Google Scholar
  40. Herbold B (1979) Bay e 9736. Salmonella/microsome test for the investigation of point mutagenic effect. PB 8213, Toxizitätsstudien. Archiv-Daten. Bayer AG, LeverkusenGoogle Scholar
  41. Herbold B (1979) Bay e 9736. Micronucleus test on the mouse for testing potential mutagenicity. PB 8264, Toxizitätsstudien. Archiv-Daten. Bayer AG, LeverkusenGoogle Scholar
  42. Herbold B (1983) Bay e 9736. Dominant lethal test on the male mouse to check for a mutagenic effect. PB 11612 (E), Toxizitätsstudien. Archiv-Daten. Bayer AG, LeverkusenGoogle Scholar
  43. Hoffmann H (1989) Placebo-kontrollierte Doppelblindstudie bei Patienten mit Hirnleistungsstörungen im Alter. Unveröffentlicht. Bayer AG, Leverkusen (unveröffentlicht)Google Scholar
  44. Hoffmeister F, Tettenborn D (1986) Calcium agonists and antagonists of the dihydropyridinetype: antinociceptive effects, interference with opiate-+b-receptoragonists and neuropharmacological actions in rodents. Psychopharmacology 90: 299–307PubMedGoogle Scholar
  45. Hoffmeister F, Benz U, Heise A, Krause HP, Neuser V (1982) Behavioral effects of nimodipine in amimals. Arzneimittelforschung/Drug Res 32: 347–360Google Scholar
  46. Holthoff VA, Heiss W-D, Pawlik G, Neveling M (1991) Positron emission tomography in nimodipine-treated patients with acute ischemic stroke. In: Scriabine A, Teasdale GM, Tettenborn D, Young W (eds) Nimodipine. Springer, Berlin Heidelberg New York Tokyo, pp 133–141Google Scholar
  47. Itil TM, Itil KZ (1985) The comparative CNS pharmacology of nimodipine in humans. In: BETZ E et al. (eds) Nimodipine: pharmacological and clinical properties. Schattauer, Stuttgart New York, pp 185–202Google Scholar
  48. Itil TM, Michael ST, Hoffmeister F, Kunitz A, Eral E (1984) Nimodipine, a calcium antagonist vasodilator with psychotropic properties (a controlled quantitative pharmaco-EEG study). Curr Ther Res 35: 405–422Google Scholar
  49. JAMES IM, SAVAGE IT (1984) Nimodipine on cerebral blood flow and alertness in man. In: Lechner H, Ladurner G (eds) Progress in pathophysiology, diagnosis and therapy of cerebrovascular diseases. Excerpta Medica, pp 142–149Google Scholar
  50. Jan M, Buchheit F, Tremoulet M (1988) Therapeutical trial of intravenous nimodipine in patients with established cerebral vasospasm after rupture of intracranial aneurysms. Neurosurgery 23: 154–157PubMedGoogle Scholar
  51. Kamath B, Lettieri J, Krol G, Raemusch K, Yeh S et al. (1986) Pharmacokinetics and metabolism of radiolabeled nimodipine. Pharmacol Res 4 [Suppl 2]: 80Google Scholar
  52. Kanda K, Fiaim SF (1986) Effects of nimodipine on cerebral blood flow in conscious rat. J P harmacol Exp Ther 236: 41–47Google Scholar
  53. Kanowski S, Fischhof P, Hiersemenzel R, Röhmel J, Kern U (1988) Wirksamkeitsnachweis von Nootropika am Beispiel von Nimodipin — ein Beitrag zur Entwicklung geeigneter klinischer Prüfmodelle. Z Gerontopsychol Gerontopsychiatr 1: 35–44Google Scholar
  54. Kapouia O, Lehrl S, Fischer B, Burkhard G, Schuback G (1990) Nimodipin bei Hirnleistungsstörungen im Alter — eine placebokontrollierte Doppelblindstudie in ärztlichen Praxen. Geriatrie und Rehabilitation 3: 135–146Google Scholar
  55. Kassell NF (1984) The natural history and treatment outcome of SAH: comments derived from the National Cooperative Aneurysm Study. In: Battye R (ed) Calcium antagonists: possible therapeutic use in neurosurgery. Proceedings of a Workshop, Dorado Beach, Puerto Rico, June 10–11, 1983, pp 62–64Google Scholar
  56. Kazda S, Hoffmeister F, Garthoff B, Towart R (1979) Prevention of the postischaemic impaired reperfusion of the brain by nimodipine (Bay e 9736). Acta Neurol Scand 60 [Suppl 72]: 302–303Google Scholar
  57. Kazda S, Garthoff B, Krause HP, Schlossmann K (1982) Cerebrovascular effects of the calcium antagonistic dihydropyridine derivative nimodipine in animal experiments. Arzneimittelforschung 32: 331–338PubMedGoogle Scholar
  58. Kazner F, Sprung CL, Adelt D, Ammerer HP, Karnick R et al. (1985) Clinical experience with nimodipine in the prophylaxis of neurological deficits after subarachnoid haemorrhage. Neurochirurgia 28 [Suppl 1]: 110–113PubMedGoogle Scholar
  59. Kieswetter H, Jung F, Radtke H, Roggenkamp G, Schneider R (1985) Investigation of the rheological effectiveness of nimodipine in comparison to other established rheologica with an in vitro stress model with calcium. In: Betz E et al. (eds) Nimodipine. Pharmacological and clinical properties. Schattauer, Stuttgart New York, pp 127–135Google Scholar
  60. Kirch W, Rämsch K-D, Dührsen U, Ohnhaus EE (1984) Clinical pharmacokinetics of nimodipine in normal and impaired renal function. Int J Clin Pharmaceut Res 4: 381–384Google Scholar
  61. Kistler JP, Ropper AH, Martin JB (1987) Cerebrovascular diseases. In: Braunwald et al. (eds) Harrison’s principles of internal medicine, 11th ed, vol 2. McGraw-Hill, New York, pp 1930— 1960Google Scholar
  62. Koos WT, PERNECZKY A, AUER LM, BöKER DK, GAAB M et al. (1985) Nimodipine treatment of ischaemic neurological deficits due to cerebral vasospasm after subarachnoid haemorrhage. Neurochirurgia 28 [Suppl 1]: 114–117PubMedGoogle Scholar
  63. Krämer G, Tettenborn D, Rothacher G, Hacke W, Busse O, Hornig CR, Aichner F, Ladurner G (1990) Nimodipine German Austrian stroke trial. Neurology 40 [Suppl 1]: 415–416Google Scholar
  64. Kroetlinger (1983) Toxizitätsstudien. Archiv-Daten. Bayer AG, LeverkusenGoogle Scholar
  65. Laursen J, Jensen F, Mikkelsen E, Jakobsen P (1988) Nimodipine treatment of subarachnoid hemorrhage. Clin Neurol Neurosurg 90: 329–337PubMedGoogle Scholar
  66. Leuschner F, Leuschner A, Schwerdtfeger W, Otto H (1976) Oral toxicity of Bay e 9736, PT 3/74 — called for short “Bay e 9736” — in rhesus monkeys. R 1143. Toxizitätsstudien. ArchivDaten. Bayer AG, LeverkusenGoogle Scholar
  67. Levere TE, Sandin M, Walker A, Ford K (1990) Facilitation of cognitive processes by nimodipine in aging. Workshop Preclinical Studies with Nimodipine, March 9–11, ScottsdaleGoogle Scholar
  68. Ljunggren B, Brandt L, Saveland H, Nilsson P-E, Cronqvist S et al. (1984) Outcome in 60 consecutive patients treated with early aneurysm operation and intravenous nimodipine. J Neurosurg 61: 864–873PubMedGoogle Scholar
  69. LJUNGGREN B, Brandt L, Säveland H (1985) Management of aneurysmal subarachnoid hemorrhage. In: Vincent JL (ed) Update in intensive care and emergency medicine. Springer, Berlin Heidelberg New York, pp 179–184Google Scholar
  70. Ljunggren BCA, Brandt JL, Säveland HG (1986) Outcome in patients subjected to early aneurysm operation and intravenous nimodipine. Minerva Med 77: 1087–1092PubMedGoogle Scholar
  71. Luiten PGM, De Jong GI, Mulder AB, Horvath E, Schuurmann T, Traber J (1989) Ultrastructural changes in microvascular morphology in the senescent rat brain: effects of long-term treatment with the calcium antagonist nimodipine. In: Traber J, Gispen WH (eds) Nimodipine and central nervous system function: new vistas. Schattauer, Stuttgart New York, pp 239–256Google Scholar
  72. Mabe H, Nagai H, Takagi T, Umemura S, Ohno M (1986) Effect of nimodipine on cerebral function and metabolic recovery following ischaemia in the rat brain. Stroke 17: 501–505PubMedGoogle Scholar
  73. Machemer L (1975) BAY e 9736. Investigation for embryotoxic and teratogenic activity after oral administration to the rat. PB 5458, Toxizitätsstudien. Archiv-Daten. Bayer AG, LeverkusenGoogle Scholar
  74. Machemer L (1977) BAY e 9736. Investigation for emryotoxic and teratogenic activity after oral administration to rabbits. PB 6993, Toxizitätsstudien. Archiv-Daten. Bayer AG, LeverkusenGoogle Scholar
  75. Machemer L (1979) BAY e 9736. Investigation of fertility and general reproductive performance in rats after oral administration. PB 8345, Toxizitätsstudien. Archiv-Daten. Bayer AG, LeverkusenGoogle Scholar
  76. Machemer L, Luckhaus G (1975a) BAY e 9736. Study of subacute toxicity in dogs given intravenous injections (4-week-experiment). PB 5335m, Toxizitätsstudien. Archiv-Daten. Bayer AG, LeverkusenGoogle Scholar
  77. Machemer L, Luckhaus G, Dycka A (1975b) BAY e 9736. Subchronic toxicity in the dog after oral administration (13 weeks study). PB 5356, Toxizitätsstudien. Archiv-Daten. Bayer AG, LeverkusenGoogle Scholar
  78. Martinez-Vila E, Guillén F, Villanueva JA, Matíasguiu J, Bigorra J, Gil P, Carbonell A, Martinezlage JM (1990) Placebo-controlled trial of nimodipine in the treatment of acute ischemic cerebral infarction. Stroke 21: 1023–1028PubMedGoogle Scholar
  79. Mayer (1988) Toxizitätsstudien. Archiv-Daten. Bayer AG, LeverkusenGoogle Scholar
  80. Mccalden TA, Nath RG, Thiele K (1984) The effects of a calcium antagonist (Nimodipine) on basal cerebral blood flow and reactivity to various agonists. Stroke 15: 527–530PubMedGoogle Scholar
  81. Mee E, Dorrance D, Lowe D, Neil-Dwyer G (1988) Controlled study of nimodipine in aneurysm patients treated early after subarachnoid haemorrhage. Neurosurgery 22: 484 491Google Scholar
  82. Menazzi D, Montenegro R, Castro JM (1985) Nimodipine in the treatment of chronic cerebrovascular insufficiency. In: Betz E, Deck K, Hoffmeister F (eds) Nimodipine. Pharmacological and clinical properties. Proceedings of the 1st International Symposium, München, Feb. 1984. Schattauer, Stuttgart New York, pp 333–344Google Scholar
  83. Meyer H, Wehinger E, Bosserk F, Scherling D (1983) Nimodipine: synthesis and metabolic pathway. Arzneimittelforschung 33: 106–112PubMedGoogle Scholar
  84. Meyer FB, Anderson RE, Yaksch TL, Sundt TM (1986) Effect of nimodipine on intracellular brain pH, cortical blood flow and EEG in experimental focal cerebral ischemia. J Neurosurg 64: 617–626PubMedGoogle Scholar
  85. Michenfelder JD, Milde (1987) Nimodipine does not affect cerebral lactate levels following complete ischaemia in dogs. J Cereb Blood Flow Metab 7: 619–624PubMedGoogle Scholar
  86. Mikus P, Aufdembinke B (1985) Nimodipine, a centrally active calcium antagonist. Results of a clinico-psychometric study. In: Betz E, Deck K, hoffmeister F (eds) Nimodipine. Pharmacological and clinical properties, Proceedings of the 1st International Symposium, München, Feb. 1984. Schattauer, Stuttgart New York, pp 329–331Google Scholar
  87. Mohamed AA, Gotoh O, Graham DI, Osborne KA, Mcculloch J et al. (1985) Effect of pretreatment with the calcium antagonist nimodipine on local cerebral blood flow and histopathology after middle cerebral artery occlusion. Ann Neurol 18: 705–711PubMedGoogle Scholar
  88. Morocurri C, Mattioli GL, Pierelli F, Prezzessere G Stefano E, Peppe A, Rizzo PA (1985) Effects of nimodipine on cefazolin induced epilepsy in rabbits. J Neurol [Suppl]: 274Google Scholar
  89. Newberg Milde L, Milde JH, Michenfelder JD (1986) Delayed treatment with nimodipine improves cerebral blood flow after complete cerebral ischaemia in the dog. J Cereb Blood Flow Metab 6: 332–337Google Scholar
  90. Nomura M (1988) Effect of nimodipine on brightness discrimination learning test in Wistar rats and spontaneously hypertensive rats. Arzneimittelforschung/Drug Res 38: 1282–1286Google Scholar
  91. Nosko M, Weir B, krueger C, Cook D, Noruus S et al. (1985) Nimodipine and chronic vasospasm in monkeys. Part 1. Clinical and radiological findings. Neurosurgery 16: 129–136PubMedGoogle Scholar
  92. Nyakas C, Markel E, Kramers RJK, Gaspar E, Bohus B, Luiten PGM (1989) Effects of nimodipine in hypoxia-induced learning and memory deficits. In: Traber J, Gispen WH (eds) Nimodipine on central nervous system function. New vistas. Schattauer, Stuttgart New York, pp 175–194Google Scholar
  93. Ohmann J, Heiskanen O (1988) Effect of nimodipine on the outcome of patients after aneurysmal subarachnoid haemorrhage and surgery. J Neurosurg 69: 683–686Google Scholar
  94. Perney TM, Hining LD, Miller RJ (1986) Different calcium channels mediate neurotransmitter release from sensory and sympathetic neurones. Biophys J 49: 200–202Google Scholar
  95. Petruk KC, West M, Mohr G, Weir BKA, Benoit B G et al. (1988) Nimodipine treatment in poor-grade aneurysm patients. J Neurosurg 68: 505–517PubMedGoogle Scholar
  96. Philippon J, Grob R, Dagreou F, Guggiari M, Rivierez M et al. (1986) Prevention of vasospasm in subarachnoid haemorrhage: a controlled study with nimodipine. Acta Neurochir 82: 110–114PubMedGoogle Scholar
  97. Pickard JD, Murray GD, Illingworth R, Shaw MDM, Teasdale GM et al. (1989) Effect of oral nimodipine on cerebral infarction and outcome after subarachnoid haemorrhage: british aneurysm nimodipine trial. Br Med J 298: 636–642Google Scholar
  98. Rämsch KD, Ahr G, Teltenborn D, Auer LM (1985a) Overview on pharmacokinetics of nimodipine in healthy volunteers and in patients with subarachnoid hemorrhage. Neurochirurgia 28: 74–78PubMedGoogle Scholar
  99. Rämsch KD, Graefe KH, Sommer J (1985b) Pharmocokinetics and metabolism of nimodipine. In: Betz E, Deck K, Hoffmeister F (eds) Nimodipine: pharmacological and clinical properties. Schattauer, Stuttgart New York, pp 147–161Google Scholar
  100. Rämsch KD, Graefe KH, Scherling D, Sommer J, Ziegler R (1986) Pharmacokinetics and metabolism of calcium-blocking agents nifedipine, nitrendipine and nimodipine. Am J Nephrol 6: 73–80PubMedGoogle Scholar
  101. Rämsch KD, Lücker PW, Wetzelsburger N (1987) Pharmacokinetics of intravenously and orally administered nimodipine. Clin Pharmacol Ther 41: 216Google Scholar
  102. Renhof M (1985a) BAY e 9736. Embryotoxicity after oral administration to rats (rearing part). PB 14010 (E), Toxizitätsstudie. Archiv-Daten. Bayer AG, LeverkusenGoogle Scholar
  103. Renhof M (1985b) BAY e 9736. Embryotoxicity rats allowed to rear the young after intravenous administration of the drug. PB 13266 (E), Toxizittsstudie. Archiv-Daten. Bayer AG, LeverkusenGoogle Scholar
  104. Renhof M (1985c) BAY e 9736. Study of the embryotoxic effects in rabbits after intravenous application. PB 13241 (E), Toxizitätsstudie. Archiv-Daten. Bayer AG, LeverkusenGoogle Scholar
  105. Roine RO, Kaste M, Kinnunen A, Nikki P, Sarna S, Kajaste S (1990) Nimodipine after resuscitation from out-of-hoospital ventricular fibrillation — a placebo-controlled, double-blind, randomized trial. J Am Med Assoc 264: 3171–3177Google Scholar
  106. Rugna RB (1982) Comparative double blind and randomized evaluation of BAY e 9736 against placebo in the geriatric area — chronic cerebrovascular insufficiency. Bayer AG, Leverkusen (unveröffentlicht)Google Scholar
  107. Saltiel E, Ellrodt AG, Monk JP, Langley MS (1988) Feldopine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension. Drugs 36: 387–428PubMedGoogle Scholar
  108. schlüter G (1986) Toxicological investigations with nimodipine. Arzneimittelforschung/Drug Res 36: 1733–1735Google Scholar
  109. Schmage N, Boehme K, Dycka J, Schmitz H (1989) Nimodipine for psychogeriatric use: methods, strategies, and considerations based on experience with clinical trials. In: Bergener M, Reisberg B (eds) Diagnosis and treatment of senile dementia. Springer, Berlin Heidelberg New York Tokyo, pp 374–381Google Scholar
  110. Schmidli J, Santilian GG, Saeed M, Palmieri D, Bing RJ (1985) The effect of nimodipine, a calcium antagonist, on intracortical arterioles in the cat brain. Curr Ther Res 38: 94–103Google Scholar
  111. Schmunk GA, Lefer AM (1982) Anti-aggregatory actions of calcium channel blockers in cat platelets. Res Commun Chem Pathol Pharmacol 35: 179–187PubMedGoogle Scholar
  112. Schuurmann T, Traber J (1989a) Old rats as an animal model for senile dementia: behavioural effects of nimodipine. In: Bergener M, Reisberg B (eds) Diagnosis and treatment of senile dementia. Springer, Berlin Heidelberg New York Tokyo, pp 295–307Google Scholar
  113. Schuurmann T, Traber J (1989b) Effects of nimodipine on behaviour of old rats. In: Traber J, Gispen WH (eds) Nimodipine and central nervous system function: new vistas. Schattauer, Stuttgart New York, pp 195–208Google Scholar
  114. Seiler RW, Grolimund P, Zurbruegg HR (1987) Evaluation of the calcium antagonist nimodipine for the prevention of vasospasm after aneurysmal subarachnoid haemorrhage. Acta Neurochir 85: 7–16PubMedGoogle Scholar
  115. Smith M-J, Kågström E, Rosén I, Siesjö BK (1983) Effect of the calcium antagonist nimodipine on the delayed hypoperfusion following incomplete ischaemia in the rat. J Cereb Blood Flow Metab 3: 543–546PubMedGoogle Scholar
  116. Spedding M, Cavero I (1984) Calcium antagonists: a class of drugs with a bright future. Part II. Determination of basic pharmacological properties. Life Sci 35: 575–587PubMedGoogle Scholar
  117. Steen PA, Newberg LA, Milde JH, Michenfelder JD (1983) Nimodipine improves cerebral blood flow and neurologic recovery after complete cerebral ischaemia in the dog. J Cereb Blood Flow Metab 3: 38–43PubMedGoogle Scholar
  118. Steen PA, Gisvold SE, Milde JH, Newberg LA, Scheithauer BW (1985) Nimodipine improves outcome when given after complete cerebral ischaemia in primates. Anesthesiology 62: 406–414PubMedGoogle Scholar
  119. Suwelack D, Weber H, Maruhn D (1985) Pharmacokinetics of nimodipine. II. Communication. Arzneimittelforschung 35: 1787–1794PubMedGoogle Scholar
  120. Takayasu IM, Bassett JE, Dacey RG (1988) Effects of calcium antagonists on intracerebral penetrating arterioles in the rat. J Neurosurg 69: 104–109PubMedGoogle Scholar
  121. Tanaka K, Gotoh F, Muramatsu F, Fukuuchi Y, Okayasu H et al. (1982) Effect of nimodipine, a calcium antagonist, on cerebral vasospasm after subarchanoid haemorrhage in cats. Arzneimittelforschung 32: 1529–1534PubMedGoogle Scholar
  122. Tettenborn D, Dycka J, Volberg E, Düdden P (1985) Blood pressure and heart rate during treatment with nimodipine in patients with subarchanoid haemorrhage. Neurochirurgia 28: 84–86PubMedGoogle Scholar
  123. Thomas A, Morey L, Aguglia E, Azzarelli O, Balsano F, Mariglino V, Caglieris N, Sterlicchio M, Capurso A, Tomasi NA, Crepaldi G, Volpe D, Palmieri G, Ambrosi G, Pow E, Cortellaro M, Zanussi C, Froldi M (1990) Nimodipine in the treatment of old age dementias. Neuro-Psychopharmacol Biol Psychiatry 14: 525–551Google Scholar
  124. Tobares N, Pedromingo A, Bigorra J (1989) Nimodipine treatment improves cognitive functions in vascular dementia. In: Bergener M, Reisberg B (eds) Diagnosis and treatment of senile dementia. Springer, Berlin Heidelberg New York Tokyo, pp 360–365Google Scholar
  125. Tollefson GD (1990) Short-term effects of the calcium channel blocker nimodipine (Bay-e9736) in the management of primary degenerative dementia. Biol Psychiatry 27: 1132–1142Google Scholar
  126. Towart R, Kazda S (1985) Effects of calcium antagonist nimodipine on isolated cerebral vessels. In: Betz E, Deck K, Hoffmeister F (eds) Nimodipine: pharmacological and clinical properties. Schattauer, Stuttgart New York, pp 147–161Google Scholar
  127. Trust Study Group (1990) Randomized, doubleblind, placebo-controlled trial of nimodipine in acute stroke. Lancet 336: 1205–1209Google Scholar
  128. Ulrich G (1987) Zur Wirkung von Nimodipin auf die topische Verteilung der absoluten Alphaleistung im EEG sowie die aktuelle Befind lichkeit gesunder Probanden. Arzneimittelforschung 37: 541–544PubMedGoogle Scholar
  129. Ulrich G, Stieglitz RD (1988) Effect of nimodipine upon electroencephalographic vigilance in elderly persons with minor impairment of brain functions. Arzneimittelforschung 38: 392–396PubMedGoogle Scholar
  130. Van Der Zee Ceem, Schuurmann T, Traber J, Gispen WH (1990) Beneficial effect of nimodipine on peripheral nerve function in aged rats. Neurobiol Aging 11: 451–456Google Scholar
  131. Van Zwieten PA (1986) Differentiation of calcium entry blockers into calcium channel blockers and calcium overload blockers. Eur Neurol 25 [Suppl 1]: 57–67PubMedGoogle Scholar
  132. Vinge E, Andersson K-E, Brandt L, Ljunggren B, Nilsson L-G et al. (1986) Pharmacokinetics of nimodipine in patients with aneurysmal subarachnoid haemorrhage. Eur J Clin Pharmacol 30: 421–425PubMedGoogle Scholar
  133. Voldby B, Petersen OF, Buhl M, Jakobsen P, Ostergaard R (1984) Reversal of cerebral arterial spasm by intrathecal administration of a calcium antagonist (nimodipine). Acta Neurochir 70: 243–254PubMedGoogle Scholar
  134. Walshe TM (1986) A study of safety and efficacy of nimodipine (BAY e 9736) for the treatment/or prevention of cognitive, behavioral, functional and affective impairments in vascular dementia. Miles Med Res Report 0755Google Scholar
  135. Young WL, Josovitz K, Morales O, Chien S (1987) The effect of nimodipine on post-ischaemic cerebral glucose utilization and blood flow in the rat. Anesthesiology 67: 54–59PubMedGoogle Scholar
  136. Zhang J, Cheng X, (1986) Effects of three cerebral vasodilators — nimodipine, nifedipine and vincamine on chemical-induced amnesia in rodents. Acta Pharm Sin 21: 731–735Google Scholar

Copyright information

© Springer-Verlag Wien 1992

Authors and Affiliations

  • H. Herrschaft

There are no affiliations available

Personalised recommendations